What is Bronchiolitis Market?
According to recent studies, around 1 in 3 children in the United Kingdom will develop bronchiolitis during their first year of life. Bronchiolitis is a common lung infection in young children and infants caused by a virus. It causes inflammation and congestion in the small airways (bronchioles) of the lung. Typically, the peak time for bronchiolitis is during the winter months. The symptoms involve coughing, wheezing, and a hard time with breathing. There are two main types of bronchiolitis including viral bronchiolitis and bronchiolitis obliterans. Viral bronchiolitis caused by a respiratory syncytial virus (RSV) in most cases. Bronchiolitis obliterans is a rare and dangerous condition seen in adults that cause scarring in the bronchioles.
The market study is being classified by Type (Viral Bronchiolitis and Bronchiolitis Obliterans) and major geographies with country level break-up.
GlaxoSmithKline PLC (United Kingdom), Hikma Pharmaceuticals (United Kingdom), Pfizer Inc. (United States), Johnson & Johnson (United States), Merck & Co. Inc. (United States), Intas Pharmaceuticals Ltd. (India), Novartis International AG (Switzerland), Cadila Healthcare Limited (India), Dr. Reddy's Laboratories Ltd (India), Fresenius SE & Co. KGaA (Germany) and Aurobindo Pharma (India) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Mylan N.V. (United States), Lupin Limited (India), Cipla Inc. (India), Endo International plc (Ireland) and Teva Pharmaceuticals Industries Ltd (Israel).
Research Analyst at AMA predicts that Global Players will contribute to the maximum growth of Global Bronchiolitis market throughout the predicted period.
Analyst at AMA have segmented the market study of Global Bronchiolitis market by Type, Application and Region.
On the basis of geography, the market of Bronchiolitis has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- Increased Prevalence of Bronchiolitis in Children
- Increased Number of Diagnostic Centres and Hospitals
- Growing Target Patient Population
- Advancement in the Medical Science
- Strengthening Distribution Channels
- Limited Patient Awareness Related to Disease Diagnosis
- No Specific Treatment Availability
- Increasing Number of Research Activities in the Field of Medical Science
- Growing Healthcare Industry Worldwide
- Stringent Regulatory Scenario
In October 2020, GlaxoSmithKline PLC (GSK) has announced that its Respiratory Syncytial Virus (RSV) candidate vaccines for maternal immunization (GSK3888550A) and older adults (GSK3844766A) were well-tolerated and highly immunogenic in Phase I/II clinical studies. The data were presented virtually at the ID Week Congress.
Key Target AudienceBronchiolitis Treatment Providers, Distributors, Emerging Companies, Research Professionals and End-users
Customization in the Report Available:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase